Success Story: Despite Receiving an RFE, an Acting Instructor in Biomedical Science Secured I-140 EB-1A Approval With Our Expert Assistance
Client’s Testimonial:
"Thank you so much for your kind message and for all your support throughout this process.”
On March 19th, 2026, we received another EB-1A (Alien of Extraordinary Ability) approval for an Acting Instructor in the Field of Biomedical Science (Approval Notice).
General Field: Biomedical Science
Position at the Time of Case Filing: Acting Instructor
Country of Origin: China
State of Residence at the Time of Filing: Washington
Approval Notice Date: March 19th, 2026
Processing Time: 4 months, 14 days (Premium Processing Upgrade Requested)
Case Summary:
Our client, who holds a Ph.D. in internal medicine, built a record in biomedical science that showed sustained impact in autoimmunity and immunopathology, particularly through discoveries on how neutrophils, B cells, and mitochondrial dysfunction drive autoimmune disease pathogenesis and reveal new biomarkers and therapeutic targets. The petition was later approved after a successful RFE response.
In presenting the case, we emphasized that the client was not simply active in biomedical science at a general level. The petition explained that her work had helped advance understanding of autoimmune disease mechanisms while also identifying biomarkers and therapeutic targets with real translational value. That framing was important because EB-1A adjudication turns on whether the evidence, viewed as a whole, shows that the client has risen to the very top of the field and achieved sustained acclaim.
The client’s publication record was a major strength. She had authored 13 peer-reviewed journal articles and 20 conference abstracts, including substantial first-authored work. In the petition, those numbers were not treated as sufficient on their own. Instead, they were tied to publication in highly selective and influential journals, which helped show that her findings had already passed rigorous peer review and were recognized as meaningful contributions by top publication venues in the field.
Citation evidence made the case even stronger. The client’s work had been cited 243 times, and the petition explained why that number carried weight. Her research was cited by independent scholars in at least 30 countries, showing broad international recognition and reliance.
Another important component was peer review. The client had conducted at least 40 reviews, and the petition explained why that was meaningful. Peer review is not just a service activity. It reflects trust from journals that depend on qualified experts to evaluate the work of other researchers.
Funding evidence further supported the client’s standing. Her work had received support from the National Institutes of Health, NIH National Center for Advancing Translational Sciences, Lupus Research Alliance, Arthritis National Research Foundation, Bristol Myers Squibb, Gilead Sciences, the National Natural Science Foundation of China, the Chinese National Key Technology R&D Program, CAMS Innovation Fund for Medical Sciences, the National High-Level Hospital Clinical Research Funding, and Boehringer Ingelheim Pharmaceuticals. In an EB-1A case, this kind of backing is significant because it reflects confidence from major public, nonprofit, and industry entities in the importance and promise of the client’s research agenda.
The case also included 6 letters of recommendation, including independent advisory opinions from internationally recognized experts who knew the client’s work through the literature rather than through personal collaboration. One expert noted:
“These many accomplishments, and her continued success in identifying new opportunities and biomedical targets, make [Client] a strong prospect for continued research positions in the United States.”
We are delighted to share that the client’s I-140 EB-1A petition was approved after a successful RFE response. It was an honor to support this case and to present the client’s record in a way that clearly showed both the depth of her scientific contributions and the extraordinary level of recognition they had already earned. We extend our sincere congratulations and best wishes for her continued success in advancing research on autoimmune disease mechanisms, biomarkers, and therapeutic strategies.